Recap
AI is revolutionizing drug discovery. But there’s a billion-dollar problem nobody talks about: Making what AI discovers. As artificial intelligence unlocks an entirely new world of molecules and potential medicines, traditional manufacturing may struggle to keep pace. In this Mashable feature, discover how eXoZymes is working to bridge the gap between AI-powered discovery and real-world production - potentially changing how tomorrow’s medicines are made.
Article excerpt
For much of the past decade, biotechnology has been defined by an extraordinary acceleration in discovery. Artificial intelligence can now predict protein structures, suggest enzyme modifications and identify promising biological pathways at a pace that would have seemed almost unimaginable only a few years ago. With digital biology, what once required months of laboratory work can increasingly be accomplished in days, allowing scientists to explore far more ideas than ever before. It is tempting to conclude that this represents the industry’s greatest remaining challenge solved. It does not. It shifts the bottleneck...